What question did this study set out to answer?

To assess the short-term efficacy and safety of vortioxetine on cognitive performance and functional capacity in adults with major depressive disorder who self-report cognitive dysfunction.

February 17, 2015NeuropsychopharmacologyOpen Access

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

View Full Paper

Ask AI

Bookmark

To assess the short-term efficacy and safety of vortioxetine on cognitive performance and functional capacity in adults with major depressive disorder who self-report cognitive dysfunction.
Multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group trial in adults aged 18–65 years with major depressive disorder receiving flexible-dose vortioxetine (10–20 mg).
Assessed the primary endpoint of change from baseline to week 8 in the Digit Symbol Substitution Test (DSST) using ANCOVA.
Evaluated key secondary endpoints hierarchically (Perceived Deficits Questionnaire [PDQ], Clinical Global Impression-Improvement [CGI-I]), alongside functional capacity (UPSA), depression severity (MADRS), and path analysis.
Vortioxetine was statistically superior to placebo on the primary endpoint of DSST cognitive performance (P < 0.05), as well as on PDQ (P < 0.01), CGI-I (P < 0.001), MADRS (P < 0.05), and UPSA functionality (P < 0.001).
Path analysis demonstrated that the cognitive improvement from vortioxetine was primarily attributable to a direct treatment effect rather than indirect mediation through depression symptom reduction.
Duloxetine did not separate significantly from placebo on the DSST or UPSA, whereas the most frequent adverse events (incidence ≥ 5%) for vortioxetine were nausea, headache, and diarrhea.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized double-blind trial demonstrates improved cognitive function with vortioxetine in major depressive disorder, indicating direct benefits beyond mood elevation.

Cite This Study

Mahableshwarkar et al. (2015) studied this question.

synapsesocial.com/papers/69dcc9aaf3d3790cb7133dac https://doi.org/10.1038/npp.2015.52

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial demonstrates improved cognitive function with vortioxetine in major depressive disorder, indicating direct benefits beyond mood elevation.

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

Key Points

Discussion

Implication

Cite This Study

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading